ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1299

Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Nathaniel Harris1, Amanda M. Eudy2 and Megan E. B. Clowse2, 1Duke University School of Medicine, Durham, NC, 2Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: outcomes, pregnancy, Rheumatic disease, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Reproductive Issues in Rheumatic Disorders Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient-reported measures of disease activity may provide useful adjuncts to physician-reported measures in identifying pregnancies at greater risk for adverse pregnancy outcomes. Little is known about the utility of these measures in SLE patients, and most analyses in patients with RA use only a single measure of disease activity or disability.

Methods: Data on pregnancy outcomes were collected on 225 patients with SLE or RA enrolled in a prospective registry at a single academic center from 2008-2016. Disease activity was measured by physician global assessment (PGA) in SLE and RA, as well as joint counts in RA. The primary patient-reported measure used was the Health Assessment Questionnaire (HAQ); we also tested the utility of pain and general health visual-analog scales. Univariate and multivariable regression models adjusted for race, education, living status, and BMI were used to assess the relationship between patient and physician-reported measures of disease activity and adverse pregnancy outcomes.

Results: Among 145 women with SLE, the mean age was 30 and 50% were African American. Among the 80 women with RA, mean age was 33; nearly 80% were white. Women with RA were more likely to be living with a spouse or partner (85% vs 68%) and were more likely to have completed at least 4 years of college (75% vs 52%). Nearly 50% of women with lupus were Ro+, and 17% percent had a history of lupus nephritis.

In women with RA, patient-reported disease activity was associated with preterm birth (OR 5.9 (95% CI: 1.5-23.9)), and gestational age (beta -1.5 weeks (-2.6, -0.4)). In addition, physician assessment of disease activity predicted preterm (OR 2.1 (1.2-3.5)) and small for gestational age births (OR 1.8 (1.03-3.1), and gestational age in weeks (beta -0.6 weeks (-0.9, -0.02)). On the other hand, for women with SLE, patient-reported measures, including HAQ, pain and global health, were not associated with adverse pregnancy outcomes. However, physician’s global assessment was associated with preterm birth (OR 2.9 (1.-6.3)), C-section delivery (OR 2.3 (1.0-5.3)), and preeclampsia (OR 2.8 (1.3-6.3)) in SLE patients. The results do not appear to be driven by nephritis or aPL syndrome.

Conclusion: Patient-reported measures of disease activity in RA patients may provide useful adjuncts for physicians to identify pregnancies at higher risk for adverse events. This suggests that increased activity on a patient-reported measure should prompt action during an RA pregnancy. In contrast, in SLE, while the physician-reported measures correlated with pregnancy outcome, the patient-reported measures did not. Our findings provide additional support for the use of patient-reported measures among women with inflammatory arthritis in pregnancy and impetus for the development of patient-reported measures that more accurately reflect lupus disease activity.


Disclosure: N. Harris, None; A. M. Eudy, None; M. E. B. Clowse, Pfizer, Janssen, 5,UCB Pharma, 5.

To cite this abstract in AMA style:

Harris N, Eudy AM, Clowse MEB. Patient-Reported Disease Activity and Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus and Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/patient-reported-disease-activity-and-adverse-pregnancy-outcomes-in-systemic-lupus-erythematosus-and-rheumatoid-arthritis/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-disease-activity-and-adverse-pregnancy-outcomes-in-systemic-lupus-erythematosus-and-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.